Vanguard Asset Management
RAPP

Vanguard Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Vanguard Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$772K Hold
18,532
– – ﹤0.01% 2010
2026
Q1 		$580K Buy
+18,532
New +$521K ﹤0.01% 2025

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Asset Management's RAPP Position: Q2 2026 in Review

Vanguard Asset Management held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 18,532 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Vanguard Asset Management first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Vanguard Asset Management held 18,532 shares of Rapport Therapeutics worth $772K as of Q2 2026.
  • Vanguard Asset Management left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2010 holding.
  • Vanguard Asset Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.